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Summary Twenty seven patients with malignant lymphoma of lymphocytic type/B-chronic lymphocytic
leukaemia (ML,L/B-CLL, Kiel classification) diagnosed from lymph node and splenectomy specimens were
studied histologically and immunologically. Lymph node biopsies showed a diffuse effacement of normal
architecture by small round lymphocytes usually with scattered proliferation centres (PC). Al spleens showed
white pulp with or without red pulp involvement, sometimes with tumour nodules present. PC-like cells or PC
were only found in the white pulp or tumour nodules.
Studies of 13 specimens using the ABC immunoperoxidase technique on frozen sections with a large panel
of monoclonal antibodies showed that although a part of the monoclonal B cell neoplasm, the proliferation
centres or splenic white pulp have a different phenotype from the surrounding cells. Some of these phenotypic
changes are similar to those reported with in vitro induction of "maturation" of ML,L/B-CLL cells. The
implications for normal B-cell development are discussed. In contrast to reported peripheral blood findings, T
cells, predominantly ofT helper phenotype in lymph nodes, were present but usually not numerous.
Malignant lymphoma of lymphocytic type (MLL -
Kiel; WDLL - Rappaport) is associated with the
presence of leukaemia of small lymphocytes of B
cell type (B-CLL). Although extensively studied
from the viewpoint of the circulating leukaemic
cells, the organisation of the neoplasm in the
affected lymph node or splenic tissue compartments
is less well known. Because peripheral blood
(Habeshaw et al., 1979) and marrow involvement
by neoplastic small lymphocytes is not of itself
sufficient for a diagnosis of MLL of B cell type, a
heterogeneous group of small cell lymphoid
neoplasms, of both B and T cell type has been
included in many studies of this disorder.
In this paper the morphological, phenotypic and
immunohistological characteristics of the affected
tissues in malignant lymphocytic lymphoma
accompanied by B cell chronic lymphocytic
leukaemia are reported, with particular attention
paid to the proliferation centres, which can be
studied only in tissue sections. Evidence is
presented. showing that proliferation centres (PC)
are not simply sites of increased mitotic activity,
but are phenotypically distinct from the
surrounding small lymphocytes. These intraclonal
phenotypic differences are similar to reported
variation in phenotype induced in CLL cells by
exposure to phorbol ester. Since the ontogeny of
the CLL B cell and its relationship to other B cell
classes is unclear, as is the role of T cells in this
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category of lymphoma, it seems important to
establish the stage of maturation arrest and
immunohistological criteria for the diagnosis of this
neoplasm.
Patient section
Twenty seven patients diagnosed at St
Bartholomew's Hospital as having malignant
lymphoma of lymphocytic type (ML,L - Kiel
(Lennert, 1978); Lukes/Collins - small lymphocytic
lymphoma (B type) (Lukes & Collins, 1974) were
selected because they had a splenectomy and/or
lymph node biopsy, and had at least one immuno-
logical study of involved tissue. Pretreatment
data were available in 21 patients. Fourteen had
a peripheral blood lymphocyte count > 15 x 1091 1P
at diagnosis and 5 of the remaining 6 subsequently
did (one had a maximum count of 10.4 x 1091-1).
Survival was calculated using life table analyses
with comparison of survivals evaluated using the
log rank test (Peto et al., 1977). Other statistical
comparisons were done using the Fisher exact test
and Chi square test.
Materials and methods
Histopathologic review
All histologic sections were reviewed (45 lymph
nodes, 9 spleens and 1 appendix). Formalin or
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formal sublimate fixed paraffin embedded sections
were stained with H and E and in most cases with
periodic-acid-Schiff, Giemsa, methyl green pyronin-
alcian blue and for reticulin. In 21 patients the
initial biopsy studied was prior to treatment (18
had been biopsied within 2 months of the original
diagnosis), while in 5, treatment (4 chemotherapy, 1
splenic irradiation) precedeed biopsy. In 1 patient
(biopsied elsewhere) the treatment status was
unknown.
Immunological studies
Cellsuspensionsweremadefrom24lymphnodesand7
spleens. Eighteen peripheral blood samples were also
studied. In nine additional cases (not included in
remainder of study) peripheral blood cells were
examined by phenotyping before and after in vitro
exposuretoTPA(100ngml-1)andsubsequentculture.
Tissue preparation and phenotyping was per-
formed as previously described (Habeshaw et al.,
1979, 1983). Monoclonality in cell suspension studies
was defined according to quantitative evaluation of
light chain class restriction (K:A ratio > 10, AiX ratio
>0.2) on viable cells before and after acetate buffer
washing; 15 patients in this series were included in the
cited publications.
Fresh tissue from 9 lymph nodes and 4 spleens
(11 patients) was snap frozen in OCT compounds,
Tissue Tek II (Lab-Tek Products, Naperville, IL),
stored at -156°C and later sectioned ( - 5gm).
Sections were fixed in acetone and immunostained
using the "ABC" avidin-biotin peroxidase
technique (Hsu et al., 1981) (ABC conjugate -
Vector Laboratories, Burlingame, CA; biotinylated
goat a-mouse IgG+M - Tago Laboratories,
Burlingame, CA). Primary antisera included
monoclonal oc-IgG, M, A, D, K and A (Seward
Laboratory, London, U.K.), Leu 1, 2a, 3a, 7,
(Becton-Dickinson, Mountainview, CA), acHLA-DR
(Dr W. Bodmer), Ti1, J5, Bi (Coulter Electronics,
Hialeah, FL), UCHT1 (Dr P. Beverley), OKT9, 10
(Dr G. Goldstein), BAI, BA2 (Dr J. Kersey, Dr T.
LeBien), 33.1 (Dr G.E. Marti, Dr T.J. Kindt), PI
153/3 (Dr M. Greaves) and biotinylated peanut
lectin (Vector Laboratories).
Endogenous alkaline phosphatase activity in
frozen sections was detected as described in detail
previously (Swerdlow et al., 1983) using the
substrate naphthol AS-MX phosphate 0.025%
pH8.6 (Sigma).
A brief summary of the reactivity of the
antibodies and other reagents that identify B cells
and their subsets based on our studies (Murray et
al., 1984) and a review of the literature are
presented in Table I (a more detailed table
including the anti-T cell antibodies is in Swerdlow
et al., 1983).
Treatment ofB-CLL cells in vitro with phorbol ester
(TPA)
PBL from patients with diagnosed B-CLL were
separated over ficoll-hypaque and cultured at
106mI -1 in Iscove's medium/10% FCS l00ngmlP-
TPA (Sigma).
After 3-5 days in culture, the phenotype of
control and TPA-treated cultures was determined
by immunofluorescence.
Results
Histopathologicfeatures
Lymph nodes Diffuse effacement of normal
architecture was present in all nodes, rarely with a
small number of residual germinal centres. The
predominant cells in all cases were small
lymphocytes with little cytoplasm and round nuclei
with clumped chromatin. Some nuclear irregularity
was noted in 22/44 biopsies, but these cells were not
typical centrocytes (cleaved cells).
Paler staining proliferation centres (PC) (Figure 1)
histologically distinct from residual germinal
centres, were present in 23/27 cases at first biopsy
(in 16/16 repeat biopsies) but were scattered over
>50% of the node in only 12 (13/16 repeat
biopsies). These differences in growth pattern (no
PC, < 50% PC, >50% PC) between first biopsy
and later biopsies was of marginal statistical
significance (P<0.05).
Thirteen (out of 27) of the first biopsies (7/16
later biopsies) showed relatively discrete and round
PC generally no larger than normal germinal
centres. In the remaining cases the PC were more
variable in size, often of irregular outline, and
sometimes confluent. Eight of the 13 patients with
the former type of PC at initial biopsy underwent
splenectomy during the period of our study,
whereas none in the latter group of 10 did
(P=0.008). At the time of splenectomy, three of the
hilar nodes showed larger irregular PC. One patient
who had no PC also underwent splenectomy.
In contrast to the surrounding lymphoma cells,
proliferation centre cells had more abundant pale
cytoplasm and slightly larger nuclei with more
dispersed chromatin (Figure 2). Some nuclei were
eccentrically placed within the cell. A variable
number of "paraimmunoblasts" (Lennert, 1978)
with medium sized, more vesicular, round nuclei
and a prominent nucleolus were also present.
Typical immunoblasts were occasionally present
within or outside the PC. Mitotic figures were often
more frequent within the PC.IMMUNOHISTOLOGY OF LYMPHOCYTIC LYMPHOMA 589
Table I Reactivity with lymphoid cells of reagents that identify B cells
Majorfrozen section
Reported reactivity immunohistological
Marker with lymphoid cells localization
Bi All B cells except plasma cells. GC>MZ cells
B-cell specific.
(Nadler et al., 1981; Stashenko et al., 1980)
BA-1, PI 153/3 All B cells except plasma cells. MZ>GC
(Abramson et al., 1981; Greaves et al., 1980)
BA-2 Early lymphoid cells. (Kersey et al., 1981) GC, not MZ
aHLA-DR All B cells except some plasma cells. GC and MZ
Early lymphoid cells.
Small subset of T cells.
(Charron & McDevitt, 1979)
33.1 1000 x stronger on EBV- GC and MZ
(DR related) transformed B cell lines
than PBL. (Marti et al., 1983)
J5 - 1% marrow cells. +weak on 6C only
- 5% cells in foetal liver.
(Ritz et al., 1981)
Peanut Some early lymphoid cells. GC only
agglutinin Cortical thymocytes.
GC B cells and plasma cells.
(Rose et al., 1981)
Endogenous MZ B cells. Occasional GC blast cell. Some MZ, occasional
alkaline (Nanba et al., 1977) GC cells
phosphatase
GC=germinal centre.
MZ=mantle zone.
PBL=peripheral blood lymphocytes.
Figure 1 Lymph node. Note the 2 distinct paler proliferation centres surrounded by the more densely packed
small round lymphocytes. (H&E, 25 x).590 S.H. SWERDLOW et al.
Figure 2 Lymph node. In addition to small round lymphocytes, the proliferation centre includes many cells
with more dispersed nuclear chromatin (short arrow) and some medium sized cells with more vesicular nuclei
("paraimmunoblasts") (long arrow). The pale cytoplasm of these cells is difficult to see here. Note the mitotic
figure in the upper left. (H&E, 100 x ).
Although all cases showing definite
lymphoplasmacytoid features were excluded from
this series, 6/26 first biopsies had at least occasional
cells with eccentric nuclei but without plasmacytoid
nuclear or cytoplasmic staining characteristics.
Similar cells were often present in nodal imprints
(Figure 3). One case had 2 isolated Dutcher Bodies.
Spleen
Three patterns of splenic involvement occurred: in 2
cases the white pulp was predominantly involved
(spleen weights 2400g, 2150g), in 2 cases there was
diffuse involvement of both red and white pulp
(600g, 600g), and in 5 cases there were focal
nodule(s) up to 2.5cm in diameter in addition to
red and white pulp infiltration (975, 2075, 2170,
2630, 3150g). The tumour nodules, which appeared
to represent coalescence of white pulp areas, had
PC in 3 cases. In all cases except one, even in the
absence of well defined PC, cells in the white pulp
had definite (3 cases) or some (5) cytological
features of PC cells (Figure 4). The cells in the red
pulp in all spleens were small round lymphocytes
with condensed chromatin. In one spleen fairly
numerous transformed cells were present including
bizarre forms, but these cells were not seen in the
hilar lymph node or in a subsequent biopsy of
involved vermiform appendix.
Immunoperoxidase and cellphenotyping studies
Immunoglobulin expression Light chain class
restricted ("monoclonal") B lymphocytes were
demonstrated on at least one occasion in 20/27
patients (13 K monoclonal; 7A monoclonal). In 5
patients, surface Ig was present but the
monoclonality of the tumour cells was not
quantitatively established and in two patients the
cells marked as SIg negative (null cells). In cases
where light chain class restriction was clearly
established, the light chain was expressed alone (3
cases) or with p heavy chain only (6 cases). Four
patients expressed p+ 5 heavy chain predominantly,
and in two of these cases p+ S expression was
accompanied by y chain expression on a minority of
cells. Seven cases were not evaluated for 5 chain
expression. In these patients, 2 expressed light chain
only, 3 expressed y chain with p chain, and 2
expressed p chain only. Surface Ig staining was
usually weak, and in cases not demonstrably
monoclonal, the occurrence of residual "cytophilic"
Ig of polyclonal type on the cell surface could not
be excluded, even after acetate buffer wash.
Frozen section Ig staining yielded comparable
results, although frozen tissue preparations were
available in only 13 of the cases (Table II). In
general frozen section staining for Ig was clearly
positive and uniform throughout the lesions. IgDIMMUNOHISTOLOGY OF LYMPHOCYTIC LYMPHOMA 591
Figure 3 Lymph node. The touch imprint illustrates the distinctive proliferation centre cells more clearly.
Note the increasing abundance of cytoplasm in the cells with larger nuclei and more dispersed chromatin. In
the largest cells, the nuclei are eccentrically placed. (Romanowsky stain, 160 x).
Figure 4 Spleen. Note the close resemblance of the paler cells present in the white pulp (on the right) to
proliferation centre cells. The cells in the red pulp (on the left) resemble the small round lymphocytes which
surround the proliferation centres (H&E, 100 x).
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Table II Comparison of light chain staining in
suspension and frozen sectionsa
Frozen section Suspension results
results MclK Mcl SIg+b SIg-
MClIK 2 0 2 0
MCIA 0 0 4 2
Mcl=monoclonal; SIg=surface immunoglobulin.
aBoth studies were done on 10 specimens.
bsIg> 10% of cells + but not clearly
monoclonal.
staining was generally weaker and detected on
fewer cells than IgM. In one case (A light chain
restricted), A positive cells were more frequent than
p+ cells, confirming that B-CLL cells can express
light chain immunoglobulin without concomitant
synthesis of heavy chain. In a further case, the
tumour cells expressed A light chain only, but node
sections showed the occurrence of polyclonal
subcaspular cortical nodules (classed as residual
lymphoid follicles) expressing both p heavy chain
and a heavy chain strongly, but lacking (
heavy chain expression.
B lymphocyte subset markers
The results obtained with B lymphocyte subset
marking monoclonal antibodies are summarized in
Tables III and IV (Figures 5 and 6) In all cases, the
tumour cells marked with Leu 1, in those areas
occupied by the monoclonal SIg/CyIg positive B
cell population. The predominant phenotype of
these cells was uniformly Leul +, BA-i +, PI
153/3+, Bl+, HLA-Dr+, 33.1+. Negative
reactions in all cases were obtained with J5, OKTIO
and peanut lectin, and all cases were negative for
endogenous alkaline phosphatase (Table III).
Antitransferrin receptor monoclonal OKT9 stained
a variable, usually small, number of cells in almost
all cases. The monoclonal BA-2, which stains
germinal centre and "early" B cells, gave positive
reactions in only 3 cases (vide infra).
Within the lesions, differential staining of the
proliferation centres and splenic white pulp areas
was noted with some antibodies (summarized in
Table IV). In lymph nodes, proliferation centres
stained more strongly with OKT9 and with the
Table HI Markers expressed by some or all
neoplastic B cells in malignant lymphocytic
lymphoma. Frozen section studies
No. ofcases examined
Marker Positive Negative
K orra 13 0
BA-1 13 0
PI 153/3b 12 0
B1 11 2
BA-2' 3 9
aHLA-DR 13 0
33.1 (HLA? DC) 13 0
PNL 0 13
J5 0 13
Alkaline phosphataseb 0 11
Leu 1 13 0
OKT9 12 1
aAll cases evaluated as monoclonal (see text).
bOne case not studied with PI 153/3. Two
cases not studied for endogenous alkaline
phosphatase.
cOne case not evaluable as + or-.
Table IV Comparison of phenotype of proliferation centres and splenic white pulp B cells with surrounding
lymphoma B lymphocytes in MLL
Sites ofgreater staining intensity orfrequency
Lymph nodes: no. ofcases Spleens: no. ofcases showing
showing describedfeature describedfeature
Monoclonal
antibody Cases studied Proliferation Surrounding No White pulp Redpulp No
or marker Node Spleen centres lymphocytes difference cells cells difference
OKT9 9 3 7 0 2 2 0 1
BI 7 4 2 0 5 3 0 1
33.1 9 4 6 0 3 3 0 1
HLA-DR 9 4 3 0 6 0 0 4
PI 153/3 8 4 0 3 5 0 1 3
BA-2 9 3 0 3 0 0 0 0
Differences were assessed only on cases showing positive staining. With monoclonal BA-2, only 3 cases
(node) showed any staining. None of the spleens examined was BA-2 positive.IMMUNOHISTOLOGY OF LYMPHOCYTIC LYMPHOMA 593
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Figure 5 Lymph node. These 3 near-serial sections illustrate the differential phenotype of proliferation
centres. Note the stronger staining of proliferation centres by T9 (A) and 33.1 (B) and the weaker staining by
PI153/3 (C). (Immunoperoxidase with haemalum counterstain, 10 x).594 S.H. SWERDLOW et al.
A B
Figure 6 Lymph node. These 2 near-serial sections show the contrast between the preferential staining of
many proliferation centres with 33.1 (A) and the preferential staining of the surrounding cells by BA-2 (B).
(Immunoperoxidase with haemalum counterstain, 10 x).
monoclonal 33.1. This latter antibody is directed
against an HLA-DC related antigen. Monoclonals
specific for non-polymorphic HLA-Dr determinants
(Da-2 or Ca-2.1 1) in section stained more cells
than 33.1, but preferentially stained the
proliferation centres in only 3 cases. The pan-B cell
reagent BI showed stronger proliferation centre
staining than the rest of the lymphoma in only 2
cases. A reverse of these patterns (i.e. stronger
staining of lymphoma cells outside proliferation
centres) was shown with the monoclonals P1 153/3
and BA-2 in 3 cases (Table IV).
Differential staining of lymphoma cells in the
spleen showed similar features to those described in
lymph nodes. The involved splenic white pulp areas
showed staining patterns analogous to the
proliferation centres in the lymph nodes (OKT9T,
33.1T with HLA-Dr expression equal). BA-2
expression was not a feature of splenic white pulp
staining (3 cases tested).
Blood CLL cells exposed to TPA in vitro showed
consistent increases in the expression of HLA-DC
antigen (monoclonal 33.1) and of HLA-DR
(monoclonal Ca2-11) (9 cases). Increase in Bl and
BA-2 staining was also observed, while expression
of the marker BA-I was consistently reduced.
Inconsistent increased expression of other markers
(C3b receptor, OKTI1 and OKTIO) was also
noted. In addition changes in growth pattern (cell
clumping, adherent cells) and cytology (enlargement
"blast cell" transformation) and increased
expression of the transferrin receptor (OKT9) and
the blast cell associated antigen BBl were evident in
TPA treated cultures.
T cell markers In suspension studies E rosette+
cells averaged 11% of cells (±11%, range 1-34%)
from 12 nodes and 2 spleens at initial biopsy. In
studies of tissue (11 nodes and 5 spleens) removed
subsequent to the initial diagnostic biopsy, E
rosetting cells averaged 12% (± 18%, range 2-17%
and 80%). In the case showing 80% of E rosetting
cells, the lymphoma population expressed A chain
on 30% of cells (A chain monoclonal).
In frozen sections T cells were present in low
frequency (<15% of cells) with one case showing
higher levels (- 30%). There was no obvious
preferential accumulation of T cells in the vicinity
of proliferation centres, as occurs near follicular
nodules in CB/CC/F lymphoma. T helper cells wereIMMUNOHISTOLOGY OF LYMPHOCYTIC LYMPHOMA 595
the predominant T cell subset in the majority of
nodes; in spleens the T suppressor subclass was
more equally represented.
Discussion
The contribution of yet another study of B-CLL to
the already voluminous literature needs to be
justified. In particular, the selection criteria applied
in this study required that all patients had one or
more tissue biopsies typical of malignant
lymphocytic lymphoma as defined in the Kiel
(Lennert, 1978) or Lukes/Collins classifications
(Lukes & Collins, 1974), equivalent to the
Rappaport class of well differentiated lymphocytic
lymphoma. In addition, all patients had at least one
phenotypic study of involved tissue confirmatory of
or compatible with this diagnosis. The occasionally
similar appearances of marrow or peripheral blood
involvement in other lymphomas, for example
lymphoplasmacytoid or centrocytic lymphoma of
small cell type, cautions that blood cell or bone
marrow cytology alone form inadequate criteria for
a definitive diagnosis of lymphocytic lymphoma.
Tissue sections, which provide evidence of cellular
organisation not present in marrow or tissue cell
suspensions, are an important element in
establishing this diagnosis.
In MLL/B-CLL, proliferation centres with their
characteristic larger and cytologically distinctive
cells (Lennert, 1978) can be recognised and studied
only in tissue section. Although generally the
phenotypic features of circulating B-CLL cells have
been assumed or reported to be similar to those in
tissues, differences in the proportions of mouse
RBC rosette forming cells have been reported
(Braylan et al., 1976; Cherchi & Catovsky, 1980;
Kettman et al., 1983).
The contribution that immunohistological studies
can make to understanding this defined class of
disease is two-fold: 1) examining the relationship of
the phenotypically distinct proliferation centre to
the unorganized circulating B cell component of the
tumour, and (2) relating MLL to what is currently
understood of B lymphocytic maturation and
development in other categories of non Hodgkin
lymphoma.
Proliferation centres
Proliferation centres can be recognized in MLL and
in the closely related lymphoma of
lymphoplasmacytoid cells (Lennert, 1978), which is
characterized by the absence of true plasma cells
but has small lymphocytes with well developed
plasmacytoid features. Proliferation centres are
distinct from germinal centres or primary follicles,
(and their neoplastic equivalents), lacking the
follicular dendritic reticulum cell and the
phenotypically and morphologically distinctive
"cleaved cell" population of centrocytes and
centroblasts always found in neoplasms of true
follicular derivation (Stein et al., 1982). In lymph
nodes involved by MLL, the proliferation centres
show no consistent anatomical localization. In the
spleen, proliferation centres and their equivalent
cells are found exclusively in the white pulp. The
association in this series between the early
appearance of discrete, round proliferation centres
in nodes and the subsequent need for splenectomy
indicates some connection between proliferation
centres of this type and the biological behaviour of
the disease. In our limited series, the approximate
area of node occupied by proliferation centres
could not be definitely related to a shorter survival
(P=0.06), and others have found no prognostic
significance (Dick & Maca, 1978). The previously
documented relationship between mitotic rate and
prognosis in MLL (Evans et al., 1978), the
concentration of mitotic figures in PC, increased
staining of PC for the transferrin receptor with
OKT9 and a previously reported retrospective
study showing a correlation between OKT9 levels
and survival in non-Hodgkin lymphoma (Habeshaw
et al., 1983) all suggest that some relationship
between PC formation and prognosis may still be
found.
Cells of the proliferation centres always expressed
the same Ig class as the small lymphocytes of the
neoplasm. Loss of IgD staining in proliferation
centres has been reported (Stein et al., 1980). B-
CLL cells have also been reported to lose IgD
expression following exposure to TPA (Cossman et
al., 1983; Totterman et al., 1981). We have not,
however, found IgD expression to be a universal
characteristic of B cells in MLL/CLL. More
significant is the finding of differential expression of
Class II MHC antigens in the proliferation centres
of MLL. HLA-Dr antigens were more strongly
expressed on PC cells than on surrounding
lymphoma cells, showing both surface and
cytoplasmic staining. TPA-induced CLL-B cells are
reported as showing increased HLA-Dr expression
(Okamura et al., 1982; Totterman et al., 1981a), as
well as HLA-Dc expression with the monoclonal
antibody Genox 353 (Guy et al., 1983). Increased
staining of PC with the monoclonal 33.1 which
detects a distinct DC-related Class II molecule
(Marti et al., 1983) could be reproduced in our
laboratory by exposure of CLL B cells to TPA as
well as increased expression of Bl and BA-2. There
is a general but not absolute consistency in the
reported phenotypic correlates of TPA effects on
CLL B cells, and the differential phenotypic
features of proliferation centre cells in tissue section
in MLL.596 S.H. SWERDLOW et al.
In vitro induction of CLL B cells with TPA is
reported as decreasing mouse RBC rosette
formation, increasing cytoplasmic Ig expression,
and increasing p chain mRNA synthesis (Cossman
et al., 1983; Forbes et al., 1981; Maeda & Deegan,
1983; Okamura et al., 1982; Totterman et al., 1980,
1981a,b). These effects represent, probably,
quantitative changes rather than "differentiation"
events, in that CLL cells can secrete IgM
(Stevenson et al., 1980, 1982), and monoclonal clg
has been reported to be present in most cases of
CLL (Gordon et al., 1983a; Guglielmi et al., 1982,
Han et al., 1982; Johnstone et al., 1982; Yasuda et
al., 1982; Newell et al., 1983).
Relationship ofB CLL cells to B cells ofother
lymphoma classes
The exact nature of the B-CLL cell is unknown,
and its normal counterpart elusive, or uncommon.
The characteristic Leul positivity of the B-CLL
cell (which is shared with T cells and certain
tonsillar and nodal B cells (Caligaris-Cappio et al.,
1982; Martin et al., 1981)), is not present on the
majority of circulating B cells in adults, which also
lack other phenotypic features of CLL B cells
(Johnstone, 1982). The main phenotypic features of
B-CLL cells also clearly distinguish them from the
follicular mantle B cells, a major subset of the B
cell population, by their Leul expression, lack of
endogenous alkaline phosphatase activity, and their
expression of cytoplasmic IgM, follicular mantle B
cells being strongly surface Ig positive and CyIg
negative (Caligaris-Cappio et al., 1982; Martin et
al., 1981; Nanba et al., 1977). B-CLL cells are
morphologically and phenotypically distinct from
germinal centre cells (Murray et al., 1984). B-CLL
cells do show phenotypic similarities with B cells
cells found in foetal or neonatal life (Gordon et al.,
1983a; Johnstone, 1982). In common with other
workers, we have found in many instances IgG on
CLL cells which is reported to represent binding by
Fc receptors (Preud'homme & Seligmann, 1972), or
to be due to rheumatoid factor-like activity. Cases
apparently expressing IgG have shown idiotypic
differences from the cell associated IgM, or IgM
and D (Stevenson et al., 1981). However, even in a
carefully selected group of patients with
homogeneous disease we, and others, have not
excluded the possibility of IgG expression (Godal &
Funderud, 1982). The reported excess of free light
chain synthesis (Gathings et al., 1981; Gordon et
al., 1983b) may be a feature of early B cells with
so-called small pre-B cell phenotype, representing a
transitional phase between cytoplasmic p chain
development, and light chain synthesis, resulting in
the capacity to produce complete H & L chain
molecules (Gordon et al., 1983b). Like B-CLL,
lymphoplasmacytoid lymphoma also exhibits
proliferation centres (Papadimitriou et al., 1979;
Stein et al., 1980), and is phenotypically similar.
Multiple myeloma also exhibits a circulating CLL-
like B cell population (Holm et al., 1977) with some
phenotypic features of CLL cells. These findings
suggest that CLL B cells would represent a
precursor population of B lymphocytes destined to
secrete antibody, but taking origin from a
differentiation pathway which does not include the
germinal centre. This pathway may be accessory to
"mainstream" B lymphocyte development, in
primary differentiation, and distinct from the T cell
dependent, secondary humoral immune responsive
memory and plasma cell pathway originating from
germinal centre.
T cell populations in B-CLL are extensively
documented, and of uncertain significance.
Increases in peripheral blood T cells (Mills &
Cawley, 1982; Platsoucas et al., 1982; Semenzato et
al., 1981) especially of the "suppressor" subset, are
not reflected in tissue sections or lymph node
suspensions, where we find TH cells to be the
predominant T cell type in most cases. Unlike the
features of follicular neoplasms, where
compartmentalization of TH cells (Tubbs et al.,
1983) and "NK cells" (Tubbs et al., 1983;
Swerdlow & Murray, 1984) occur within the
follicular lesions, both TH cells and Leu7+ cells
occur as apparent random elements in MLL
(Swerdlow & Murray, 1984). T cells are not of the
malignant clone in B-CLL (Gharton et al., 1980;
Yunis et al., 1982; Fialkow et al., 1978). T
suppressor cells in our study were most commonly
in the spleen, as others have shown (Kay et al.,
1982).
In summary, malignant lymphocytic lymphoma
(B-CLL) is a histologically defined and
phenotypically consistent entity. The proliferation
centres, characteristic of this condition, show
changes in MHC Class II antigen expression, and
other phenotypic features interpretable as
"maturation" of the neoplastic clone, and similar to
the effects of "inducers of differentiation" such as
phorbol ester on B-CLL cells. These cells have few
affinities to B cells of germinal centres, and MLL is
definitely distinct from lymphomas of follicular
class (CB/CC/F, MLCC and MLCB). Close
ontogenic relationships between CLL B cells, and
lymphoplasmacytoid lymphoma cells can be
inferred from phenotypic studies. We conclude that
the CLL-B cell, as a class, is representative of a
precursor of secretory B cells (plasma cells) which
may arise from differentiation pathways distinct
from the T cell dependent development pathway
related to germinal follicle formation.IMMUNOHISTOLOGY OF LYMPHOCYTIC LYMPHOMA 597
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